Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMorgan Advanced Materials Regulatory News (MGAM)

Share Price Information for Morgan Advanced Materials (MGAM)

Share Price is delayed by 15 minutes
Get Live Data
228.00    -1.50 (-0.65%)
Bid:
227.00
Ask:
227.50
Spread: 0.50 (0.22%)
Market Cap: £630.23m
MGAM Live PriceLast checked at - London Stock Exchange

Intraday Morgan Advanced Materials Share Chart

Trading Update

5 Nov 2024 07:00

RNS Number : 8969K
Morgan Advanced Materials PLC
05 November 2024
 

Press Release

Morgan Advanced Materials plc

5 November 2024

Trading Update

Expanded simplification programme, and

Commencement of a £40m share buy-back programme

Morgan Advanced Materials plc, the global manufacturer of advanced carbon and ceramic materials for technically demanding applications, announces today a trading update for the first nine months to 30 September 2024 with an outlook for the current financial year, an expanded simplification programme and the commencement of a share buy-back programme of up to £40m.

Current Trading

Sales for the first nine months of the year to 30 September 2024 were 3.8% higher for the Group on an organic constant currency basis, compared to the same period last year. By reporting segment, organic constant-currency sales performance for the nine months to September 2024, was as follows:

 

Thermal Products -2.3%

Performance Carbon +12.6%

Technical Ceramics +3.4%

2024 Outlook

Market conditions have weakened during the second half and we are now seeing a further deterioration in our outlook for the fourth quarter. Our outlook for constant currency revenue growth for the full financial year is now around 3%. Together with additional FX headwinds, we now expect an adjusted operating profit margin for the year of c.11.4%.

Expansion of Simplification Programme

Our simplification programme, announced in March 2024, included restructuring that was expected to deliver £10 million of annualised savings by 2025 with an expected implementation cost of around £20m incurred over 2023 to 2025. Our increased focus on simplification has now allowed us to expand this programme in order to achieve further cost reductions in our supply chain and back office, and in order to help us return adjusted operating profit margin to our target range in 2025. We expect to deliver an additional £12m of annualised savings with an associated exceptional charge of around £25m incurred over 2024 to mid-2026 (resulting in expected overall programme savings of £22m with an exceptional charge of £45m).

Our expected overall investment in both simplification and growth remains unchanged, as we allocate capital to the near term cost opportunity in weaker markets in preference to capacity investment in core industrial markets.

Expected returns from our previously announced investment in Faster Growing Markets also remains unchanged.

Announcement of a Share Buy-back Programme

The Group is pleased to announce the commencement of a share buy-back programme of up to £40m. The programme reflects the Group's strong prospects and balance sheet, which have allowed us to increase returns to shareholders by supplementing our regular dividend with the launch of this share buy-back programme.

Whilst we continue to pursue acquisition targets in line with our strict criteria, we expect that the timing of any likely transaction is such that a share buy-back programme can now be prioritised, in line with our capital allocation policy. The Group continues to target through the cycle leverage range of 1.0x to 1.5x net debt to adjusted EBITDA excluding M&A, and expects to remain within this range during 2025.

Further detail is provided in a separate RNS released today.

Pete Raby, Chief Executive Officer, said:

"We are seeing a weaker trading environment in the near term and are expanding our simplification programme, continuing our track record of self-help. We remain focused on delivering enhanced returns to shareholders and are pleased to be able to support this in the near term with the additional cost savings and share buy-back programme, both announced today. Our business is well positioned with leading market positions, a strong balance sheet, and attractive opportunities in both faster growth and core markets as markets recover."

 

For further enquiries:

Pete Raby, CEO

Richard Armitage, CFO

Morgan Advanced Materials plc

01753 837000

 

Nina Coad

Brunswick

0207 404 5959

 

This announcement contains inside information. The person responsible for arranging the release of this announcement on behalf of Morgan Advanced Materials plc is Richard Armitage, Chief Financial Officer. The Company's LEI number is I4K14LL95N2PHDL7EG85.

Notes to editors

1. Simplification Programme

£ million

FY 2023

FY 2024

FY 2025

FY 2026

FY 2027

Total

Announced March 2024

Adjusted operating profit benefit (incremental)

1

7

10

Costs charged to specific adjusting items

(7)

(11)

(2)

(20)

Announced November 2024

Adjusted operating profit benefit (incremental)

6

12

12

Costs charged to specific adjusting items

(5)

(15)

(5)

(25)

 

2. Our financial framework

As previously announced, our financial framework is:

- Organic constant currency revenue growth of 4% - 7% through the cycle.

- Adjusted operating profit margin of 12.5% to 15.0%

- Return on invested capital of 17.0% to 20.0%

- Leverage (net debt/EBITDA excl. leasing) of 1.0x to 1.5x without M&A, 1.5x to 2.0x with M&A

 

3. This announcement contains forward-looking statements. These statements have been made in good faith based on the information available up to the time of the approval of this announcement. No assurance can be given that these expectations will prove to have been correct. By their nature, forward-looking statements involve risks, uncertainties or assumptions that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. As such, undue reliance should not be placed on forward-looking statements..

The Directors undertake no obligation to update any forward-looking statements whether as a result of new information, future events or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFFFIILALSIIS
Date   Source Headline
26th Sep 202312:24 pmRNSDirector/PDMR Shareholding
16th Aug 202311:27 amRNSDirector/PDMR Shareholding
7th Aug 20235:24 pmRNSDirector/PDMR Shareholding
4th Aug 20237:00 amRNSHalf-Year Results for Period Ended 30 June 2023
13th Jul 20234:49 pmRNSDirector/PDMR Shareholding
5th Jul 20234:51 pmRNSDirector/PDMR Shareholding
29th Jun 20235:06 pmRNSResult of AGM
29th Jun 20237:00 amRNSH1 Trading Update
22nd Jun 202311:50 amRNSBlock listing Interim Review
31st May 20233:52 pmRNSDirector/PDMR Shareholding
26th May 20233:28 pmRNSNotice of Annual General Meeting 2023
24th May 20233:59 pmRNSDirector/PDMR Shareholding
11th May 202312:06 pmRNSDirector/PDMR Shareholding
11th May 202312:01 pmRNSDirector/PDMR Shareholding
11th May 202311:59 amRNSDirector/PDMR Shareholding
9th May 20235:59 pmRNSDirector/PDMR Shareholding
4th May 20235:28 pmRNSAnnual Report & Accounts 2022
3rd May 20235:38 pmRNSDirector/PDMR Shareholding
3rd May 20235:28 pmRNSDirector/PDMR Shareholding
28th Apr 20235:45 pmRNSInformation required by DTR 4.1
28th Apr 20237:00 amRNSFull-year results for the period ended 31 Dec 2022
13th Apr 20237:00 amRNSNotification of Full-Year Results
7th Feb 20237:00 amRNSUpdate on Trading and Cyber Security Incident
18th Jan 20237:00 amRNSAppointment of Chair Designate
10th Jan 20237:00 amRNSNotice of Cyber Security Incident
22nd Dec 202211:01 amRNSBlock listing Interim Review
16th Dec 20224:44 pmRNSHolding(s) in Company
6th Dec 20227:00 amRNSAccelerated Pension Contribution
6th Dec 20227:00 amRNSCapital Markets Event
23rd Nov 202210:01 amRNSDirector/PDMR Shareholding
15th Nov 20225:06 pmRNSDirector/PDMR Shareholding
10th Nov 20228:03 amRNSDirector Declaration
4th Nov 20227:00 amRNSTrading Update
17th Oct 20222:21 pmRNSDirector/PDMR Shareholding
26th Sep 202212:52 pmRNSDirector/PDMR Shareholding
26th Sep 202212:49 pmRNSDirector/PDMR Shareholding
29th Jul 20227:00 amRNSHalf-year results
15th Jun 20229:30 amRNSBlock listing Interim Review
1st Jun 202210:00 amRNSDirector/PDMR Shareholding
31st May 202210:06 amRNSDirector/PDMR Shareholding
24th May 20222:32 pmRNSDirector/PDMR Shareholding
16th May 20222:52 pmRNSDirector/PDMR Shareholding
5th May 20223:12 pmRNSDirectorate Change
5th May 20222:00 pmRNSResult of AGM
5th May 20227:00 amRNSQ1 trading update
3rd May 20222:45 pmRNSHolding in Company
14th Apr 20222:59 pmRNSHolding(s) in Company
30th Mar 20223:25 pmRNSAnnual Financial Report
28th Mar 202212:00 pmRNSHolding in Company
23rd Mar 202211:02 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.